The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment - A European multicentre study

International Clinical Psychopharmacology

Volumn 31, Issue 1, 2016, Pages 1-7

  Höfer, Peter ^a   Schosser, Alexandra ^b,c   Calati, Raffaella ^e   Serretti, Alessandro ^f   Massat, Isabelle ^g   Kocabas, Neslihan A ^g,h   Konstantinidis, Anastasios ^b,d   Mendlewicz, Julien ^g   Souery, Daniel ^g   Zohar, Joseph ⁱ   Juven Wetzler, Alzbeta ⁱ   Montgomery, Stuart ^j   Kasper, Siegfried ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Zentrum Für Seelische Gesundheit Leopoldau   (Austria)

^d Zentrum für Seelische Gesundheit Muldenstrasse   (Austria)

^e INSERM U1061   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^h GAZI UNIVERSITY   (Turkey)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

5HTR1A; 5HTR2A; pharmocogenetics; suicidality

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; TREATMENT RESPONSE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EUROPE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK; STATISTICS AND NUMERICAL DATA;

ADULT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EUROPE; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RISK; SUICIDE; SUICIDE, ATTEMPTED;

EID: 84951566644     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000101     Document Type: Article

References (47)

1. Alda M, Hrdina PD. (2000). Distribution of platelet 5-HT(2A) receptor densities in suicidal and non-suicidal depressives and control subjects. Psychiatry Res 94: 273-277
2. Antypa N, Calati R, Souery D, Pellegrini S, Sentissi O, Amital D, et al. (2013). Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. J Affect Disord 150: 649-652
3. Antypa N, Serretti A, Rujescu D. (2013). Serotonergic genes and suicide: a systematic review. Eur Neuropsychopharmacol 23: 1125-1142
4. Berlim MT, Turecki G. (2007). What is the meaning of treatment resistant/refractory major depression (TRD)?. A systematic review of current randomized trials. Eur Neuropsychopharmacol 17: 696-707
5. Bondy B, Buettner A, Zill P. (2006). Genetics of suicide. Mol Psychiatry 11: 336-351
6. Brent DA, Mann JJ. (2005). Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet 133C: 13-24
7. Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun A, et al. (2010). A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 153B: 1465-1473
8. Davies S, Naik PC, Lee AS. (2001). Depression, suicide, and the national service framework. BMJ 322: 1500-1501
9. De Luca V, Likhodi O, Kennedy JL, Wong AH. (2007). Differential expression and parent-of-origin effect of the 5-HT2A receptor gene C102T polymorphism: analysis of suicidality in schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 144B: 370-374
10. Fanous AH, Chen X, Wang X, Amdur R, ONeill FA, Walsh D, Kendler KS. (2009). Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families. Am J Med Genet B Neuropsychiatr Genet 150B: 411-417
11. Fernández-Navarro P, Vaquero-Lorenzo C, Blasco-Fontecilla H, Díaz-Hernández M, Gratacòs M, Estivill X, et al. (2012). Genetic epistasis in female suicide attempters. Prog Neuropsychopharmacol Biol Psychiatry 38: 294-301
12. González-Castro TB, Tovilla-Zárate CA, Juárez-Rojop I, Pool García S, Genis A, Nicolini H, López Narváez L. (2013). Association of 5HTR1A gene variants with suicidal behavior: case-control study and updated meta-Analysis. J Psychiatr Res 47: 1665-1672
13. Hamilton M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
14. Harris EC, Barraclough B. (1997). Suicide as an outcome for mental disorders. A meta-Analysis. Br J Psychiatry 170: 205-228
15. Höfer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, et al. (2013). The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-A European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci 263: 385-391
16. Illi A, Setälä-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, et al. (2009). 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20: 1125-1128
17. Judy JT, Seifuddin F, Mahon PB, Huo Y, Goes FS, Jancic D, et al. (2012). Association study of serotonin pathway genes in attempted suicide. Am J Med Genet B Neuropsychiatr Genet 159B: 112-119
18. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al., National Comorbidity Survey Replication. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCSR). JAMA 289: 3095-3105
19. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, et al. (2013). The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-Analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 263: 105-118
20. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23: 8788-8799
21. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. (2004). Association of the C (-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7: 501-506
22. Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, Millard WJ. (2007). Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 11: 155-160
23. Li D, Duan Y, He L. (2006). Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-Analysis. Biochem Biophys Res Commun 340: 1006-1015
24. Macgregor S, Khan IA. (2006). GAIA: an easy-To-use web-based application for interaction analysis of case-control data. BMC Med Genet 7: 34
25. Mann JJ. (2002). A current perspective of suicide and attempted suicide. Ann Intern Med 136: 302-311
26. Mann JJ. (2003). Neurobiology of suicidal behavior. Nat Rev Neurosci 4: 819-828
27. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814
28. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, et al. (2010). 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 25: 228-231
29. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266-1277
30. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A. (2007). No health without mental health. Lancet 370: 859-877
31. Rao ML, Hawellek B, Papassotiropoulos A, Deister A, Frahnert C. (1998). Upregulation of the platelet Serotonin2A receptor and low blood serotonin in suicidal psychiatric patients. Neuropsychobiology 38: 84-89
32. Rockett IR, Kapusta ND, Bhandari R. Suicide misclassification in an international context: revisitation and update. Suicidology Online 2011; 2: 48-61
33. Ruhé HG, Huyser J, Swinkels JA, Schene AH. (2006). Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 189: 309-316
34. Ruhé HG, Huyser J, Swinkels JA, Schene AH. (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67: 1836-1855
35. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S. (2012). European Group for the Study of Resistant Depression (GSRD)-Where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 22: 453-468
36. Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Papageorgiou K, et al. (2012). The impact of COMTgene polymorphisms on suicidality in treatment resistant major depressive disorder-A European multicenter study. Eur Neuropsychopharmacol 22: 259-266
37. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. (2001). Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 11: 375-380
38. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. (2004). The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 7: 453-460
39. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. (1998). Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 18: 7394-7401
40. Stoltenberg SF, Christ CC, Highland KB. (2012). Serotonin system gene polymorphisms are associated with impulsivity in a context dependent manner. Prog Neuropsychopharmacol Biol Psychiatry 39: 182-191
41. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. (1999). Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9: 83-91
42. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al., Group for the Study of Resistant Depression. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68: 1062-1070
43. Suominen K, Isometsä E, Suokas J, Haukka J, Achte K, Lönnqvist J. (2004). Completed suicide after a suicide attempt: a 37-year follow-up study. Am J Psychiatry 161: 562-563
44. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al., STAR D Study Team. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR.∗D: implications for clinical practice. Am J Psychiatry 163: 28-40
45. WHO. (2012). Programmes and Projects, Mental Health. Available at: http://www. who.int/mental-health/management/depression/definition/en/ [Accessed 17 March 2012]
46. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 655-679
47. World Health Organization. (2000). World Health Report 2000 Health Systems: Improving Performance. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/whr/2000/en/whr00-en.pdf [Accessed 14 May 2012].